Biopharma SHAKTI commits Rs. 10,000 crore to scale biologics manufacturing, translational research, and supply chains over five years, a strategic bet on biosimilars, advanced therapies, and domestic capacity. The fund aims to foster industry-academia incubators, incentives for advanced production, and a stronger export orientation. If executed, the scheme could reduce import dependence, lower therapy costs, and attract global investment into India’s next-generation drug industry. This measure requires clear timelines and state-level coordination.
Trending
- 64 Best Songs About Growing Up & Coming of Age
- Most Americans oblivious to Social Security’s projected demise
- What we know about Israel's criminal investigations
- Bangladesh Schools Show Healthy Habits but Gaps in Health Support
- Could Social Security’s 2027 COLA Be Lower Than 2026’s? Here’s the Truth.
- Woman Gives $1 Million in ‘Life-Changing’ Bonuses to Teachers in Her School District
- New Social Security forecast is great (and rare) news for US retirees — how to take full advantage now
- 20 “Notes to Self” We Need to Read 20 Times a Day (Until They Sink In)
Thursday, August 20
